20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
BioNTech SE (BNTX) operates in the BIOTECHNOLOGY industry and is headquartered in Mainz, Germany with about 7,807 employees. Its market capitalization is roughly $24 billion. In the fiscal year ended 2025-12-31, BNTX reported €2.8B in revenue and (€1.1B) in net income.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Interactive charts & full statements → Open the BNTX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €2.6B | €2.8B | €2.8B | €3.8B | €17.3B | €19.0B | €482M | €109M | €128M | €62M |
| Gross Profit | €1.9B | €2.1B | €2.2B | €3.2B | €14.3B | €16.1B | €423M | €91M | €114M | €52M |
| Gross Margin % | 70.8% | 77.6% | 80.3% | 84.3% | 82.7% | 84.7% | 87.7% | 84.0% | 89.3% | 84.9% |
| Operating Income (EBIT) | (€1.9B) | (€624M) | (€1.3B) | €690M | €12.6B | €15.3B | (€82M) | (€182M) | (€54M) | (€61M) |
| Operating Margin % | -71.8% | -22.6% | -47.8% | 18.1% | 73.0% | 80.5% | -17.1% | -167.1% | -42.2% | -99.5% |
| Net Income | (€1.7B) | (€1.1B) | (€665M) | €930M | €9.4B | €10.3B | €15M | (€179M) | (€48M) | (€86M) |
| Net Margin % | -64.0% | -39.6% | -24.2% | 24.4% | 54.5% | 54.2% | 3.1% | -164.9% | -37.6% | -139.1% |
| EBITDA | (€941M) | (€628M) | (€367M) | €1.4B | €13.1B | €15.0B | (€105M) | (€144M) | (€24M) | (€75M) |
| Earnings Per Share (EPS) | €-6.73 | €-4.51 | €-2.77 | €3.83 | €37.77 | €39.63 | €0.06 | €-0.85 | €-0.21 | €-0.38 |
| Shares Outstanding (M) | 253M | 242M | 240M | 243M | 250M | 260M | 249M | 211M | 227M | 227M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | €106M | €120M | €899M | €1.5B | €261M | €183M | €1.2B | €1.2B |
| Gross Profit | €9M | (€76M) | €569M | €1.4B | €184M | €99M | €946M | €1.1B |
| Gross Margin % | 8.1% | -63.2% | 63.3% | 90.2% | 70.7% | 54.2% | 79.5% | 85.6% |
| Operating Income (EBIT) | (€948M) | (€672M) | (€231M) | (€47M) | (€501M) | (€534M) | €149M | €10M |
| Operating Margin % | -897.8% | -559.8% | -25.7% | -3.1% | -192.1% | -292.2% | 12.5% | 0.8% |
| Net Income | (€821M) | (€541M) | (€302M) | (€29M) | (€387M) | (€416M) | €260M | €198M |
| Net Margin % | -777.3% | -450.4% | -33.6% | -1.9% | -148.2% | -227.5% | 21.8% | 15.9% |
| EBITDA | (€585M) | (€450M) | (€56M) | €149M | (€348M) | (€369M) | €464M | €211M |
| Earnings Per Share (EPS) | €-3.24 | €-2.14 | €-1.23 | €-0.12 | €-1.60 | €-1.73 | €1.08 | €0.81 |
| Shares Outstanding (M) | 253M | 253M | 245M | 239M | 242M | 240M | 240M | 245M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | €737M | €438M | €208M | €5.4B | €13.6B | €890M | (€14M) | (€198M) | (€58M) | (€53M) |
| Capital Expenditures (CapEx) | €218M | €168M | €452M | €706M | €363M | €154M | €85M | €71M | €68M | €58M |
| Free Cash Flow (FCF) | €518M | €270M | (€245M) | €4.7B | €13.2B | €736M | (€99M) | (€270M) | (€126M) | (€110M) |
| FCF Margin % | 19.6% | 9.8% | -8.9% | 122.2% | 76.3% | 3.9% | -20.5% | -248.2% | -98.8% | -179.1% |
| Dividends Paid | — | — | €0M | €0M | €484M | €0M | €0M | €0M | €0M | €0M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | €11M | (€428M) | €299M | €855M | €132M | (€822M) | (€501M) | (€688M) |
| Capital Expenditures (CapEx) | €56M | €58M | €62M | €43M | €568M | €651M | €100M | €91M |
| Free Cash Flow (FCF) | (€45M) | (€486M) | €238M | €811M | (€436M) | (€1.5B) | (€602M) | (€779M) |
| FCF Margin % | -42.4% | -404.6% | 26.4% | 53.4% | -167.1% | -805.3% | -50.6% | -62.6% |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | €20.3B | €22.0B | €22.5B | €23.0B | €23.3B | €15.8B | €2.3B | €798M | €653M | €375M | €390M |
| Cash & Cash Equivalents | €9.7B | €7.7B | €9.8B | €11.7B | €13.9B | €1.7B | €1.2B | €519M | €411M | €172M | €304M |
| Total Liabilities | €2.6B | €2.8B | €3.1B | €2.8B | €3.2B | €3.9B | €947M | €304M | €386M | €423M | €358M |
| Total Debt (Short + Long-Term) | €316M | €267M | €254M | €219M | €212M | €302M | €240M | €77M | €12M | €19M | €3M |
| Total Shareholders' Equity | €17.8B | €19.2B | €19.4B | €20.2B | €20.1B | €11.9B | €1.4B | €493M | €266M | (€49M) | €30M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BNTX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms